• Publications
  • Influence
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Recent progress in chimeric antigen receptor-modified T-cell (CAR-T cell) technology in cancer therapy is extremely promising, especially in the treatment of patients with B-cell acute lymphoblasticExpand
  • 78
  • 6
Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion
Background Ductal carcinoma in situ with microinvasion (DCIS-Mi) generally has favorable prognosis, but the long-term outcomes of DCIS-Mi and the biologic evolution from ductal carcinoma in situExpand
  • 23
  • 4
  • PDF
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab‐CD3), showed greatExpand
  • 33
  • 2
Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
Purpose Few studies has documented early relapse in luminal B/HER2-negative breast cancer. We examined prognostic factors for early relapse among these patients to improve treatment decision-making.Expand
  • 31
  • 1
  • PDF
Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
Aim The current study aimed to explore the distribution patterns of 21-gene recurrence score (RS) assay in Chinese early breast cancer patients. Methods Nine hundred and eighty consecutive estrogenExpand
  • 15
  • 1
  • PDF
Prognostic and predictive value of Ki-67 in triple-negative breast cancer
This study was to investigate the prognostic role of Ki-67 in further classification of triple negative breast cancer (TNBC), and to test whether high expression level of Ki67 can predict benefitExpand
  • 28
  • 1
  • PDF
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
Background The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain. Methods Both electronic databases and proceedingsExpand
  • 28
  • 1
  • PDF
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicityExpand
  • 8
  • 1
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors
Efficacy data from the KATHERINE clinical trial, comparing the HER2-directed antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to trastuzumab in patients with early-stageExpand
  • 10
  • 1
Photothermal Targetting therapy of A20 Mouse Lymphoma model using Anti CD-138 Antibody conjugated Gold Nanospheres
The aim of this study was to investigate the therapeutic effects of photothermal targeting of hollow gold nanospheres on lymphoma. Hollow gold nanospheres were modified by PEG (polyethylene glycol)Expand
  • 2
  • 1
...
1
2
3
4
...